Aduro Biotech (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
April 15 2015 - 6:00AM
What:
Aduro Biotech, Inc. (Nasdaq:ADRO), a clinical-stage cancer
immuno-oncology company, will visit the Nasdaq MarketSite in Times
Square in celebration of its initial public offering (IPO), which
will occur today, April 15.
In honor of the occasion, Stephen T. Isaacs, Chairman,
President and Chief Executive Officer will ring the
Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Wednesday, April 15, 2015 – 9:15 a.m. to 9:30 a.m.
ET
Aduro Biotech Media Contact:
Sylvia R. Wheeler
(510) 809-9264
swheeler@aduro.com
Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram
Page:
http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos visit Tumblr
Page:
http://nasdaq.tumblr.com/
Webcast: A webcast of the Nasdaq Opening Bell
will be available at: https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of
the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on
the market open of your choice.
About Aduro Biotech
(Nasdaq:ADRO):
Aduro Biotech, Inc. is a clinical-stage immuno-oncology company
focused on the development of technology platforms to stimulate an
immune response against cancer. Aduro’s lead platform is based on
proprietary strains of live-attenuated, double-deleted (LADD)
Listeria monocytogenes that induce a potent innate immune response
and have been engineered to express tumor-associated antigens to
induce tumor-specific T cell-mediated immunity. Aduro has received
Breakthrough Therapy designation from the FDA for its lead LADD
regimen, CRS-207 in combination with GVAX Pancreas in pancreatic
cancer. The company is evaluating the proprietary immuno-oncology
combination in the ongoing Phase 2b ECLIPSE clinical trial and has
additional ongoing clinical trials with its LADD platform in
mesothelioma and glioblastoma. The company is also developing
clinical candidates using cyclic dinucleotide (CDN) synthetic small
molecule immune modulators that are designed to activate the
intracellular STING receptor, a central mediator of the innate
immune response. For more information, please visit
www.aduro.com.
About Nasdaq:
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing,
exchange technology, listing, information and public company
services across six continents. Through its diverse portfolio of
solutions, Nasdaq enables customers to plan, optimize and execute
their business vision with confidence, using proven technologies
that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first
electronic stock market, its technology powers more than 70
marketplaces in 50 countries, and 1 in 10 of the world's securities
transactions. Nasdaq is home to more than 3,500 listed companies
with a market value of over $9.1 trillion and more than 10,000
corporate clients. To learn more, visit www.nasdaq.com/ambition or
www.business.nasdaq.com.
-NDAQA-
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nasdaq (NASDAQ:NDAQ)
Historical Stock Chart
From Apr 2023 to Apr 2024